135 related articles for article (PubMed ID: 28691332)
1. Advocacy, communication, and partnerships: Mobilizing for effective, widespread cervical cancer prevention.
Wittet S; Aylward J; Cowal S; Drope J; Franca E; Goltz S; Kuo T; Larson H; Luciani S; Mugisha E; Schocken C; Torode J
Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():57-62. PubMed ID: 28691332
[TBL] [Abstract][Full Text] [Related]
2. Ending cervical cancer: A call to action.
Aranda S; Berkley S; Cowal S; Dybul M; Evans T; Iversen K; Moeti M; Osotimehin B; Peterson S; Piot P; Purandare CN; Sidibé M; Trimble T; Tsu VD
Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():4-6. PubMed ID: 28691327
[TBL] [Abstract][Full Text] [Related]
3. Executive summary.
Vaccine; 2012 Nov; 30 Suppl 4():xi. PubMed ID: 23510772
[No Abstract] [Full Text] [Related]
4. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
5. Attitudes toward cervical cancer screening among women receiving human papillomavirus vaccination in a university-hospital-based community: interim 2-year follow-up results.
Miyagi E; Sukegawa A; Motoki Y; Kaneko T; Maruyama Y; Asai-Sato M; Numazaki R; Mizushima S; Hirahara F
J Obstet Gynaecol Res; 2014 Apr; 40(4):1105-13. PubMed ID: 24428631
[TBL] [Abstract][Full Text] [Related]
6. Scaling up cervical cancer screening in the midst of human papillomavirus vaccination advocacy in Thailand.
Yothasamut J; Putchong C; Sirisamutr T; Teerawattananon Y; Tantivess S
BMC Health Serv Res; 2010 Jul; 10 Suppl 1(Suppl 1):S5. PubMed ID: 20594371
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
8. The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries.
Campos NG; Sharma M; Clark A; Lee K; Geng F; Regan C; Kim J; Resch S
Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():47-56. PubMed ID: 28691334
[TBL] [Abstract][Full Text] [Related]
9. The investment case for cervical cancer elimination.
Tsu VD; Ginsburg O
Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():69-73. PubMed ID: 28691328
[TBL] [Abstract][Full Text] [Related]
10. 'Lest we forget' as we move forward with cervical screening.
Saville M; McNally O
Aust N Z J Obstet Gynaecol; 2018 Jun; 58(3):265-266. PubMed ID: 29864221
[No Abstract] [Full Text] [Related]
11. The path to eliminate cervical cancer in the world and the challenges of professional education.
Bosch FX
Vaccine; 2012 Nov; 30 Suppl 4():viii-ix. PubMed ID: 23510770
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
13. Cervical cancer prevention in Australia: Planning for the future.
Saville AM
Cancer Cytopathol; 2016 Apr; 124(4):235-40. PubMed ID: 26619381
[TBL] [Abstract][Full Text] [Related]
14. Modeling cervical cancer prevention in developed countries.
Kim JJ; Brisson M; Edmunds WJ; Goldie SJ
Vaccine; 2008 Aug; 26 Suppl 10(Suppl 10):K76-86. PubMed ID: 18847560
[TBL] [Abstract][Full Text] [Related]
15. Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries.
Steben M; Jeronimo J; Wittet S; Lamontagne DS; Ogilvie G; Jensen C; Smith J; Franceschi S
Vaccine; 2012 Nov; 30 Suppl 5():F183-91. PubMed ID: 23199962
[TBL] [Abstract][Full Text] [Related]
16. The Global Alliance for Vaccines and Immunization (GAVI).
Schwalbe N
Vaccine; 2012 Nov; 30 Suppl 4():x. PubMed ID: 23510771
[No Abstract] [Full Text] [Related]
17. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus vaccine policy and delivery in Latin America and the Caribbean.
Andrus JK; Lewis MJ; Goldie SJ; García PJ; Winkler JL; Ruiz-Matus C; de Quadros CA
Vaccine; 2008 Aug; 26 Suppl 11():L80-7. PubMed ID: 18945405
[TBL] [Abstract][Full Text] [Related]
19. Cervical cancer: a call for political will.
Pollack AE; Balkin MS; Denny L
Int J Gynaecol Obstet; 2006 Sep; 94(3):333-42. PubMed ID: 16857201
[TBL] [Abstract][Full Text] [Related]
20. Innovative public-private partnership: a diagonal approach to combating women's cancers in Africa.
Oluwole D; Kraemer J;
Bull World Health Organ; 2013 Sep; 91(9):691-6. PubMed ID: 24101785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
